We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
- Authors
Cannon, Christopher P; Curtis, Sean P; FitzGerald, Garret A; Krum, Henry; Kaur, Amarjot; Bolognese, James A; Reicin, Alise S; Bombardier, Claire; Weinblatt, Michael E; van der Heijde, Désirée; Erdmann, Erland; Laine, Loren; MEDAL Steering Committee
- Abstract
Cyclo-oxygenase-2 (COX-2) selective inhibitors have been associated with an increased risk of thrombotic cardiovascular events in placebo-controlled trials, but no clinical trial has been reported with the primary aim of assessing relative cardiovascular risk of these drugs compared with traditional non-steroidal anti-inflammatory drugs (NSAIDs). The MEDAL programme was designed to provide a precise estimate of thrombotic cardiovascular events with the COX-2 selective inhibitor etoricoxib versus the traditional NSAID diclofenac.
- Publication
Lancet (London, England), 2006, Vol 368, Issue 9549, p1771
- ISSN
1474-547X
- Publication type
Journal Article
- DOI
10.1016/S0140-6736(06)69666-9